Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China

Published:2016-04 Issue: Volume: Page:2287
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Zhou Ping,Jiang Yi-Zhou,Hu Xin,Sun Wei,Liu Yi-Rong,Liu Fang,Luo Rong-Cheng,Shao Zhi-Ming

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients;Therapeutic Advances in Medical Oncology;2024-01

2. Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis;International Journal of Cancer;2022-10-24

3. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond;Expert Opinion on Biological Therapy;2021-04-01

4. Establishment of a type II insulin‑like growth factor receptor gene site‑integrated SKBR3 cell line using CRISPR/Cas9;Oncology Letters;2020-10-11

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes

;Cancer Management and Research;2020-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP